These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 15788366

  • 1. Stereoselective inhibition of cytochrome P450 forms by lansoprazole and omeprazole in vitro.
    Liu KH, Kim MJ, Shon JH, Moon YS, Seol SY, Kang W, Cha IJ, Shin JG.
    Xenobiotica; 2005 Jan; 35(1):27-38. PubMed ID: 15788366
    [Abstract] [Full Text] [Related]

  • 2. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
    Li XQ, Andersson TB, Ahlström M, Weidolf L.
    Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
    Lasker JM, Wester MR, Aramsombatdee E, Raucy JL.
    Arch Biochem Biophys; 1998 May 01; 353(1):16-28. PubMed ID: 9578596
    [Abstract] [Full Text] [Related]

  • 8. Identification and relative contributions of human cytochrome P450 isoforms involved in the metabolism of glibenclamide and lansoprazole: evaluation of an approach based on the in vitro substrate disappearance rate.
    Naritomi Y, Terashita S, Kagayama A.
    Xenobiotica; 2004 May 01; 34(5):415-27. PubMed ID: 15370958
    [Abstract] [Full Text] [Related]

  • 9. Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes.
    Liu KH, Lee YM, Shon JH, Kim MJ, Lee SS, Yoon YR, Cha IJ, Shin JG.
    Xenobiotica; 2004 May 01; 34(5):429-38. PubMed ID: 15370959
    [Abstract] [Full Text] [Related]

  • 10. Enantiomer/enantiomer interactions between the S- and R- isomers of omeprazole in human cytochrome P450 enzymes: major role of CYP2C19 and CYP3A4.
    Li XQ, Weidolf L, Simonsson R, Andersson TB.
    J Pharmacol Exp Ther; 2005 Nov 01; 315(2):777-87. PubMed ID: 16093273
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
    Zvyaga T, Chang SY, Chen C, Yang Z, Vuppugalla R, Hurley J, Thorndike D, Wagner A, Chimalakonda A, Rodrigues AD.
    Drug Metab Dispos; 2012 Sep 01; 40(9):1698-711. PubMed ID: 22648560
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes.
    Abelö A, Andersson TB, Antonsson M, Naudot AK, Skånberg I, Weidolf L.
    Drug Metab Dispos; 2000 Aug 01; 28(8):966-72. PubMed ID: 10901708
    [Abstract] [Full Text] [Related]

  • 15. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
    Wen X, Wang JS, Backman JT, Kivistö KT, Neuvonen PJ.
    Drug Metab Dispos; 2001 Nov 01; 29(11):1359-61. PubMed ID: 11602509
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes.
    Miura M, Tada H, Yasui-Furukori N, Uno T, Sugawara K, Tateishi T, Suzuki T.
    Eur J Clin Pharmacol; 2004 Nov 01; 60(9):623-8. PubMed ID: 15448955
    [Abstract] [Full Text] [Related]

  • 17. Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro.
    Chang SY, Li W, Traeger SC, Wang B, Cui D, Zhang H, Wen B, Rodrigues AD.
    Drug Metab Dispos; 2008 Dec 01; 36(12):2513-22. PubMed ID: 18787056
    [Abstract] [Full Text] [Related]

  • 18. Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor.
    VandenBranden M, Ring BJ, Binkley SN, Wrighton SA.
    Pharmacogenetics; 1996 Feb 01; 6(1):81-91. PubMed ID: 8845864
    [Abstract] [Full Text] [Related]

  • 19. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples.
    Yamazaki H, Inoue K, Shaw PM, Checovich WJ, Guengerich FP, Shimada T.
    J Pharmacol Exp Ther; 1997 Nov 01; 283(2):434-42. PubMed ID: 9353355
    [Abstract] [Full Text] [Related]

  • 20. Oxidative metabolism of lansoprazole by human liver cytochromes P450.
    Pichard L, Curi-Pedrosa R, Bonfils C, Jacqz-Aigrain E, Domergue J, Joyeux H, Cosme J, Guengerich FP, Maurel P.
    Mol Pharmacol; 1995 Feb 01; 47(2):410-8. PubMed ID: 7870052
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.